

Era of Hope

Department of Defense
Breast Cancer Research
Program Meeting

September 25-28, 2002
Orange County Convention Center
Orlando, Florida

PROGRAM

About the Meeting

MEETING INTENT

The Era of Hope Meeting is designed for the reporting of studies congressionally funded by the innovative U.S. Department of Defense (DOD) Breast Cancer Research Program (BCRP). Scientists, physicians, breast cancer survivors and advocates, policymakers, and the general public will come together to learn about advancements made since the Program's inception. This international meeting provides a unique forum for experts in different fields and research areas to gather, share their ideas, and identify promising directions in breast cancer research.

Investigators funded by the DOD BCRP in FY98-00 are obliged to attend the meeting and report on their research findings. Some FY99-00 Concept Awardees and FY92-97 Principal Investigators will present at the meeting. In addition, consumer participation is a hallmark of the program and an integral part of the Era of Hope Meeting. Consumers who have supported the BCRP have been invited to speak, co-chair sessions, and attend the meeting.

UNIFYING THEMES AND FORMAT

The Era of Hope Meeting has been organized around three unifying themes:

- ❖ *The Role of Signal Transduction Pathways in Breast Cancer Development and Progression*
- ❖ *Latest Advancements in the Field of Breast Cancer Prevention*
- ❖ *Identification and Characterization of Molecular Targets That Can Serve as the Basis for Individualized Breast Cancer Therapy*

A mix of DOD awardees and other renowned scientists, physicians, consumers, and healthcare providers will address these topics in a variety of sessions. Sessions are designed to progress from basic science through translational research to the clinical perspective, as well as provide the impacts on the consumer. In addition, research on breast cancer spanning from precancer/early cancer through metastasis will be presented.

The meeting opens on Wednesday evening, September 25, 2002, with Frances M. Visco, George W. Sledge, Jr., and Jeffrey Trent presenting an Opening Keynote Session on the *Past 10 Years: Next 10 Years*. Each of the next 3 days begins with Early Educational A.M. Sessions. The daily Keynote and Plenary Sessions coincide with one of the three unifying themes. Interactive Sessions or a Town Hall Meeting will be held each day. These sessions are designed to engage the audience and to address important current issues in breast cancer.

Focused Symposia and Poster Sessions, highlighting the research of the DOD grantees, are the heart of the conference. Key leaders in each research field and prominent breast cancer consumers will preside over the Symposia. As co-chairs, they will provide a brief overview, introduce and facilitate platform presentations, summarize discussions, and highlight the impacts of the research on breast cancer. The Poster Sessions provide a forum for discussion about progress and experiences, and to share novel approaches to difficult research questions and challenges.

Each day will also have an Innovation Session to include presentations that challenge the attendees to dare to be innovative and creative in designing strategies to solve breast cancer problems. As we look to the future of breast cancer research, some of the DOD BCRP predoctoral and postdoctoral awardees will be highlighted at a special lunch session for New Investigators.

CONTENTS

About the Meeting	2
Letter from the Commanding General of the United States Army Medical Research and Materiel Command	3
Letter from the Director of Congressionally Directed Medical Research Programs	4
Leadership	6
Questions and Floor Plans	8
Presenters	10
General Information	13
Continuing Education Accreditation	15
Technical Program at a Glance	16
Agenda	20
Posters at a Glance	38
Poster Sessions	39
Poster/Author Index	119
Notes	158

TECHNICAL PLANNING COMMITTEE

The Era of Hope DOD BCRP Technical Planning Committee (TPC) and its subcommittees have designed a program for the reporting of studies congressionally funded by the innovative DOD BCRP since its inception. This year's meeting will be particularly special in that it marks the 10th anniversary of the DOD BCRP. Scientists, physicians, breast cancer survivors and advocates, policymakers, and the general public will come together to learn about the advancements made over the history of the program and to explore ways to eradicate the disease.

Lynn M. Matrisian, Ph.D.

TPC Conference Co-Chair, Integration Panel (IP) Chair

Professor and Chair, Department of Cancer Biology,
Vanderbilt University School of Medicine

M. Carolina Hinestrosa

TPC Conference Co-Chair, IP Member

Nueva Vida

Patricia C. Modrow, Ph.D.

Conference Chair

Congressionally Directed Medical Research Programs
(CDMRP), U.S. Army Medical Research and Materiel
Command (USAMRMC)

Carol A. Evans

Program Representative

Deputy Manager, Biomedical Technology Division,
Science Applications International Corporation (SAIC)

Anna D. Barker, Ph.D.

President and CEO, BIO-NOVA, Inc.

Wendie A. Berg, M.D., Ph.D.

Director, Breast Imaging, University Imaging Center,
University of Maryland

Leslie Bernstein, Ph.D.

Scientific Co-Chair for September 27

Professor of Preventive Medicine and Senior Associate
Dean, University of Southern California (USC) School of
Medicine, USC/Norris Comprehensive Cancer Center

Kenneth L. Bertram, M.D., Ph.D.

Colonel, U.S. Army Medical Corps; Director, CDMRP,
USAMRMC

Mary Lenora Disis, M.D.

Scientific Co-Chair for September 27

University of Washington - Oncology

William N. Hait, M.D., Ph.D.

Scientific Co-Chair for September 28

Director, The Cancer Institute of New Jersey
Robert Wood Johnson Medical School

Richard H. Kenyon, Ph.D.

Breast Cancer Research Program Manager, CDMRP,
USAMRMC

Ngina Lythcott, Dr. P.H.

Consumer Co-Chair for September 27

Breast Cancer Liaison, National Black Women's Health
Project, Vice Dean, Mailman School of Public Health,
Columbia University

Rosemary Rosso, J.D.

Consumer Co-Chair for September 26

Greater Baltimore-Washington Breast Cancer Group

Dennis J. Slamon, M.D., Ph.D.

Chief, Division of Hematology-Oncology; Director of
Clinical and Translational Research at the Jonsson
Comprehensive Cancer Center, UCLA School of Medicine

George W. Sledge, Jr., M.D.

Professor of Medicine, Ballve-Lantero Professor
of Oncology, Indiana Cancer Pavilion

Patricia S. Steeg, Ph.D.

Scientific Co-Chair for September 26

Chief, Women's Cancers Section,
Laboratory of Pathology, National Cancer Institute

Frances M. Visco, Esq.

Consumer Co-Chair for September 28

President, National Breast Cancer Coalition

Stacey Young-McCaughan, R.N., Ph.D.

Lieutenant Colonel, U.S. Army Nurse Corps; Chief,
Outcomes Management, Quality Management, U.S. Army
Medical Command

Julie K. Zadinsky, R.N., Ph.D.

Colonel, U.S. Army Nurse Corps; Deputy Chief of Staff for
Regulatory Compliance and Quality, CDMRP, USAMRMC

Leadership

TPC SUBCOMMITTEES:

Abstract

George W. Sledge, Jr., M.D. (Chair)
Carlos L. Arteaga, M.D.
Vimla Band, Ph.D.
Anna D. Barker, Ph.D.
James Babilion, Ph.D.
Leslie Bernstein, Ph.D.
John M. Boone, Ph.D.
Myles Cabot, Ph.D.
Graham Casey, Ph.D.
Mary Lenora Disis, M.D.
Kay Dickersin, Ph.D.
Kunio Doi, Ph.D.
Gloria Heppner, Ph.D.
M. Carolina Hinestrosa
Laurence N. Kolonel, M.D., Ph.D.
Lawrence H. Kushi, Sc.D.

Ngina Lythcott, Dr. P.H.
H. Kim Lyerly, M.D.
Marlene McCarthy
Lynn M. Matrisian, Ph.D.
Daniel Medina, Ph.D.
Arthur Mercurio, Ph.D.
Vasilis Ntziachristos, Ph.D.
William H. Redd, Ph.D.
Rosemary Rosso, J.D.
Irma Russo, M.D.
Dennis J. Slamon, M.D., Ph.D.
David I. Smith, Ph.D.
Saraswati Sukumar, Ph.D.
Patricia S. Steeg, Ph.D.
Kenneth D. Tew, Ph.D.
Frances M. Visco, Esq.

Consumer

M. Carolina Hinestrosa, (Chair)
Kay Dickersin, Ph.D.
Ngina Lythcott, Dr. P.H.
Marlene McCarthy
Rosemary Rosso, J.D.
Frances M. Visco, Esq.

Media

Anna D. Barker, Ph.D. (Chair)
Edward Bresnick, Ph.D.
Ngina Lythcott, Dr. P.H.
Lynn M. Matrisian, Ph.D.
Dennis J. Slamon, M.D., Ph.D.
Frances M. Visco, Esq.

BCRP LEADERSHIP

Responding to the National Breast Cancer Coalition's efforts to increase research aimed at overcoming breast cancer, Congress appropriated funds to the DOD in FY92-02 to be directed toward breast cancer research. The USAMRMC was given responsibility for managing the BCRP. A management team of scientists, headed by Colonel Kenneth A. Bertram, dedicates themselves to the fight against breast cancer. An Integration Panel provides scientific and consumer expertise to fulfill the goals of the Program.

Lester Martinez-Lopez, M.D., M.P.H.

Major General, U.S. Army Medical Corps; Commanding, USAMRMC

Kenneth A. Bertram, M.D., Ph.D.

Colonel, U.S., Army Medical Corps; Director, CDMRP, USAMRMC

Melissa A. Forsythe, Ph.D.

Colonel, U.S. Army Nurse Corps; Deputy Director, CDMRP, USAMRMC

Richard H. Kenyon, Ph.D.

Program Manager for BCRP, CDMRP, USAMRMC

Patricia C. Modrow, Ph.D.

Conference Chair; CDMRP, USAMRMC

Katherine H. Moore, Ph.D.

Grants Manager, BCRP, CDMRP, USAMRMC

Carole Christian, Ph.D.

Grants Manager, BCRP, CDMRP, USAMRMC

Naba Bora, Ph.D.

Grants Manager, BCRP, CDMRP, USAMRMC

INTEGRATION PANEL MEMBERS

The U.S. Army gratefully acknowledges the intellectual strength and vision that past and present Integration Panel members have provided in crafting a BCRP that has received accolades from Congress, and from both the scientific and consumer communities.

Current Integration Panel Members are:

Executive Committee

Lynn M. Matrisian, Ph.D., Chair
Dennis J. Slamon, M.D., Ph.D., Chair Emeritus
Patricia S. Steeg, Ph.D., Chair-Elect
Anna D. Barker, Ph.D., Member-at-Large (*Former Chair*)
Frances M. Visco, Esq., Member-at-Large (*Former Chair*)

Members

Wendie A. Berg, M.D., Ph.D.
Leslie Bernstein, Ph.D.
Edward Bresnick, Ph.D.
Laurie L. Fajardo, M.D.
Barbara A. Given, Ph.D.
M. Carolina Hinestrosa
Peter A. Jones, Ph.D., D.Sc.
Laurence N. Kolonel, M.D., Ph.D.
Ngina Lythcott, Dr. P.H.
Daniel Medina, Ph.D.
Abram Recht, M.D.
William H. Redd, Ph.D.
Rosemary Rosso, J.D.
George W. Sledge, Jr., M.D.
Geoffrey M. Wahl, Ph.D.

Questions and Floor Plans



QUESTIONS



Overall Direction/Media:

Erika Petersen, SAIC

Manager, Conferences and Media Relations

Phone: (301) 698-5991 Fax: (301) 698-6188

e-mail: eohadmin@us-frederick.mail.saic.com

Consumers/Speakers Reimbursements:

Mary McConnell, SAIC

Phone: (301) 698-5991 Fax: (301) 698-6188

e-mail: eohadmin@us-frederick.mail.saic.com

Abstracts/Poster Presentations/Audiovisual:

Rob Watson, SAIC


Abstract and Conference Coordinator

Phone: (301) 698-5991 Fax: (301) 698-6188

e-mail: eohadmin@us-frederick.mail.saic.com


Era of Hope website: <http://cdmrp.army.mil/bcrp/era>

Rosen Centre Hotel




Floor Plans


Orange County Convention Center



**Early Morning
Educational, Interactive,
and Symposia Sessions**



**Poster
Sessions**



**Opening, Plenary,
Keynote, Innovation, and
Town Hall Sessions**

Presenters

INVITED SPEAKERS AND CO-CHAIRS

Carlos L. Arteaga, M.D.

Division of Hematology/Oncology,
Vanderbilt University

Anna D. Barker, Ph.D.

President and CEO, BIO-NOVA, Inc.

Patricia Barr

National Breast Cancer Coalition

James P. Babilion, Ph.D.

Center for Molecular Imaging
Research, Massachusetts General
Hospital East

Jeffrey Berenberg, Ph.D.

Colonel, U.S. Army Medical Corps
Chief, Hematology-Oncology Service
Tripler Army Medical Center

Leslie Bernstein, Ph.D.

Senior Associate Dean, Faculty Affairs
AFLAC, Incorporated, Chair in Cancer
Research; Professor, Preventive
Medicine Keck School of Medicine at
the USC

Donald A. Berry, Ph.D.

Professor and Chairman,
Department of Biostatistics,
University of Texas, M.D. Anderson
Cancer Center

Kenneth L. Bertram, M.D., Ph.D.

Colonel, U.S. Army Medical Corps,
Director, CDMRP, USAMRMC

Diane F. Birt, Ph.D.

Department of Food Science and
Human Nutrition, Iowa State
University

Mina J. Bissell, Ph.D.

Director, Life Sciences Division,
Lawrence Berkeley National
Laboratory

John D. Boice, Jr., Sc.D.

Scientific Director, International
Epidemiology Institute and Professor
of Medicine, Vanderbilt University
Medical Center and Vanderbilt Ingram
Cancer Center

David Botstein, Ph.D.

Professor, Department of Genetics,
Stanford University School of
Medicine

Vernal H. Branch

UCSF Breast SPORE Advocacy Core

Christine A. Brunswick

Vice President, National Breast Cancer
Coalition

Christine B. Carpenter

Iowa Breast Cancer Edu-action

Graham Casey, Ph.D.

Cancer Biology Department, Lerner
Research Institute, Cleveland Clinic
Foundation

Ann F. Chambers, Ph.D.

Professor, Department of Oncology,
University of Western Ontario

Diane Z. Chase

National Breast Cancer Coalition

Thomas L. Chenevert, Ph.D.

Department of Radiology-MRI,
University of Michigan Health System

Diana Chingos

Chairman, USC/Norris Cancer
Survivorship Advisory Council

Graham A. Colditz, M.D., Dr. P.H.

Professor of Medicine,
Harvard Medical School

Nancy E. Davidson, M.D.

Professor of Oncology, Johns Hopkins
School of Medicine

Channing J. Der, Ph.D.

Lineberger Comprehensive Cancer
Center, University of North Carolina

Kay Dickersin, Ph.D.

Associate Professor, Brown University
Medical School, Department of
Community Health

Mary Lenora Disis, M.D.

University of Washington - Oncology

Arlyne Draper

Y-ME of San Diego

Dale Eastman

Alamo Breast Cancer Foundation

Mary A. Elliott

Susan G. Komen Breast Cancer
Foundation

Ana Garcia

Big Island Breast Cancer Coalition

Julia M. W. Gee, Ph.D.

Tenovus Centre for Cancer Research,
Welsh School of Pharmacy, Cardiff
University

Maryellen L. Giger, Ph.D.

Professor of Radiology and the College
Director, Graduate Programs in
Medical Physics, University of
Chicago

Venus Ginés

Director, Dia de la Mujer Latina, Inc.

Michael N. Gould, Ph.D.

Kelly H. Clifton Professor of
Oncology, McArdle Laboratory for
Cancer Research, University of
Wisconsin-Madison

Joe W. Gray, Ph.D.

Professor of Laboratory Medicine and
Radiation Oncology; Program Leader,
Cancer Genetics and Breast Oncology,
UCSF Comprehensive Cancer Center

Bettye L. Green

African American Women in Touch

David Gur, Sc.D.

Professor, University of Pittsburgh

William N. Hait, M.D., Ph.D.

Director, The Cancer Institute of New
Jersey, Robert Wood Johnson Medical
School

Kathleen Harris

Founding Member/Past President,
Wisconsin Breast Cancer Coalition

Elaine S. Hill

Co-Founder and President of the
Board, Y-ME of Chattanooga

M. Carolina Hinestrosa

Nueva Vida

Anthony Howell, M.B.B.S., F.R.C.P.

Professor of Medical Oncology,
Department of Medical Oncology,
Christie Hospital NHS Trust

Luisa Iruela-Arispe, Ph.D.

Associate Professor,
Department of Molecular, Cell, and
Developmental Biology - UCLA,
Molecular Biology Institute - UCLA

Ismail Jatoi, M.D., Ph.D., F.A.C.S.

U.S. Army Medical Corps, Chief of
Surgery, U.S. Army Hospital,
Heidelberg, Germany

Presenters

Roy A. Jensen, M.D.

Associate Professor of Pathology and Cancer Biology, Vanderbilt University Medical Center

Elaine M. Kaime, M.D. F.A.C.P.

Captain, U.S. Navy Medical Corps, Director of Breast Health Center, Naval Medical Center, San Diego, California

Dean Kamen

Founder and President, DEKA Research and Development Corporation

Katherine A. Kennedy, Ph.D.

Professor of Pharmacology, Department of Pharmacology, George Washington University

Keith L. Knutson, Ph.D.

Tumor Vaccine Group, University of Washington

Michael Lagios, M.D.

Associate Professor of Clinical Pathology, Stanford University

Betsy Lambert, J.D.

SHARE

Wen-Hwa Lee, Ph.D.

Department of Molecular Medicine/IBT, University of Texas Health Science Center at San Antonio

Mildred Leigh-Gold

Women Supporting Women Support Group

Barron Lerner, M.D.

Associate Professor of Medicine and Public Health, Columbia University (Author of the *Breast Cancer Wars*)

Liz Lostumbo

Greater Baltimore-Washington Breast Cancer Group

Herbert Kim Lyerly, M.D.

Duke University Medical Center

Ngina Lythcott, Dr. P.H.

Breast Cancer Liaison, National Black Women's Health Project

Wish Martin

President, Sister Surviving, Inc.

Lester Martinez-Lopez, M.D., M.P.H.

Major General, U.S. Army Medical Corps; Commanding, USAMRMC

Suleiman Alfred Massarweh, M.D.

Oncology-Hematology Fellow Breast Center, Baylor College of Medicine

Lynn M. Matrisian, Ph.D.

Chair, Department of Cancer Biology, Ingram Distinguished Chair of Cancer Research, Vanderbilt University School of Medicine

Carol Matyka

CARE Advocates

Musa Mayer

SHARE

Marlene C. McCarthy

Chair, Rhode Island Breast Cancer Coalition

John J. McCormack, Ph.D.

Professor of Pharmacology and Medicine, Department of Pharmacology, University of Vermont College of Medicine

Paul S. Meltzer, M.D., Ph.D.

Head, Section of Molecular Genetics, Cancer Genetics Branch, National Human Genome Research Institute

Sofia D. Merajver, M.D., Ph.D.

University of Michigan Health System

Arthur M. Mercurio, Ph.D.

Director, Division of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School

Suzanne Miller, Ph.D.

Fox Chase Cancer Center

Patricia C. Modrow, Ph.D.

Conference Chair, CDMRP, USAMRMC

Kirsten Moysich, Ph.D.

Assistant Professor, Roswell Park Cancer Institute

William J. Muller, Ph.D.

Institute of Molecular Biology and Biotechnology, Hamilton, Ontario, Canada

Sharyl Nass, Ph.D.

Institute of Medicine

Karin D. Noss

Y-ME National Breast Cancer Organization

Christine K. Norton

President/Co-Founder, Minnesota Breast Cancer Coalition

David Parkinson, M.D.

Vice President, Novartis Pharmaceutical Corporation

Renata Pasqualini, Ph.D.

Associate Professor of Medicine and Cancer Biology, University of Texas, M.D. Anderson Cancer Center

Ellen Passel

Metropolitan Washington National Breast Cancer Coalition

Jennifer A. Pietenpol, Ph.D.

Associate Professor of Biochemistry, Associate Director of Basic Research, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine

Richard J. Pietras, M.D., Ph.D.

Associate Professor of Medicine, UCLA School of Medicine

Michael F. Press, M.D., Ph.D.

University of Southern California, Norris Comprehensive Cancer Center

Cathie Ragovin, M.D.

Secretary, Massachusetts Breast Cancer Coalition

Rebecca Blanchard Raftogianis, Ph.D.

Associate Member, Department of Pharmacology, Fox Chase Cancer Center

Mark J. Ratain, M.D.

University of Chicago

Abram Recht, M.D.

Beth Israel Deaconess Medical Center

William H. Redd, Ph.D.

Mt. Sinai-New York City Medical Center

Janardan K. Reddy, M.D.

Magerstadt Professor and Chairman, Department of Pathology, Northwestern University, The Feinberg School of Medicine, Chicago

Jane Reese-Coulbourne

Susan G. Komen Breast Cancer Foundation

Presenters

Sylvia G. Rickard

Utah Breast Cancer Network

Beverly Rockhill, Ph.D.

Department of Epidemiology,
School of Public Health,
University of North Carolina

Sjoerd Rodenhuis, M.D.

Chairman of Medicine and Medical;
Director, The Netherlands Cancer
Institute; Professor of Medical
Oncology, University of Amsterdam

Jeffrey M. Rosen, Ph.D.

Department of Molecular and Cellular
Biology, Baylor College of Medicine

Rosemary Rosso, J.D.

Greater Baltimore-Washington Breast
Cancer Group

Diana Rowden

Past Chair, National Board, Susan G.
Komen Breast Cancer Foundation

Connie Rufenbarger

Trustee and Director of Program
Development, Catherine Peachey
Fund, Inc.

Irma H. Russo, M.D., F.C.A.P.

Breast Cancer Research Laboratory,
Fox Chase Cancer Center

Jose Russo, M.D.

Breast Cancer Research Laboratory,
Fox Chase Cancer Center

Nancy Ryan

Chair, New Hampshire Breast Cancer
Coalition

Jeffrey L. Salisbury, Ph.D.

Tumor Biology Program Director,
Mayo Clinic

David Savitz, Ph.D.

Chair, Department of Epidemiology,
School of Public Health,
University of North Carolina

Thomas A. Sellers, Ph.D.

Mayo Clinic Cancer Center

Dennis C. Sgroi, M.D.

Assistant Professor of Pathology,
Harvard University,
Massachusetts General Hospital

Brian R. Shappell

Trustee of Catherine
Peachey Fund, Inc.

Eve Sánchez Silver

Cinta Latina, The Atlantic Breast
Health Initiative

Helen Schiff

SHARE

Joy Simha

Founder, Young Survival Coalition

Dennis J. Slamon, M.D., Ph.D.

Division of Hematology - Oncology,
Department of Medicine, UCLA
School of Medicine

George W. Sledge, Jr., M.D.

Professor of Medicine, Ballve-Lantero
Professor of Oncology, Indiana Cancer
Pavilion

Michael B. Sporn, M.D.

Department of Pharmacology,
Dartmouth Medical School

Patricia S. Steeg, Ph.D.

Chief, Women's Cancers Section,
Laboratory of Pathology,
National Cancer Institute

Richard G. Stevens, Ph.D.

Department of Community Medicine,
University of Connecticut Health
Center

Henry J. Thompson, Ph.D.

Senior Scientist and Chair,
Center for Nutrition in the Prevention
of Disease, AMC Cancer Research
Center

Deborah Toppmeyer, M.D.

Associate Professor of Medicine,
The Cancer Institute of New Jersey

Jeffrey M. Trent, Ph.D.

Scientific Director;
Chief, Cancer Genetics Branch,
National Human Genome Research
Institute, National Institutes of Health

Mary C. Tunson

Board Member, After Breast Cancer
Diagnosis, Inc.

Nicole Urban, Sc.D.

Full Member, Fred Hutchinson Cancer
Research Center

Alex W. Valadez, Ph.D.

Academy Associates, Inc.

Frances M. Visco, Esq.

President, National Breast Cancer
Coalition

Barbara Vonderhaar, Ph.D.

Chief, Molecular and Cellular
Endocrinology Section, Basic
Research Laboratory, National Cancer
Institute

Geoffrey M. Wahl, Ph.D.

The Salk Institute

Sandy Walsh

Co-Founder, Y-ME, Davis (CA)
Affiliate

Claudia E. Wayne, Esq.

National Breast Cancer Coalition

Robert A. Weinberg, Ph.D.

Member, Whitehead Institute for
Biomedical Research

Danny R. Welch, Ph.D.

Associate Professor of Pathology and
Pharmacology, Pennsylvania State
University College of Medicine

Douglas Yee, M.D.

Professor of Medicine and
Pharmacology, University of
Minnesota Cancer Center

Kathleen Zeitz, J.D.

Nebraska Lead Coordinator, National
Breast Cancer Coalition

General Information

All events will start and end on time. Your promptness and consideration for the speakers who have devoted significant time to the preparation of outstanding presentations are deeply appreciated.

MEETING LOCATION

Orange County Convention Center
9800 International Drive, Orlando, Florida 32819
Phone: 407-685-9800

THIS IS A NON-SMOKING MEETING.

REGISTRATION & INFORMATION CENTER

Orange County Convention Center Registration Concourse

All participants must register for the meeting. The registration fee provides (1) admittance to all scientific and poster sessions, (2) meals and refreshments concurrent with the Technical Program sessions, and (3) one copy of the Conference Proceedings and Program Booklet, plus conference materials. The sole intent of the registration fee is to promote, enhance, and facilitate technical discussions and long-term professional relationships/collaborations.

NAME BADGES

Name badges must be worn at all times for admission to the meetings, poster sessions, and all receptions.

ON-SITE REGISTRATION HOURS

Wednesday, September 25, 2002, 12:00 noon – 8:00 p.m.
Thursday, September 26, 2002, 7:00 a.m. – 7:00 p.m.
Friday, September 27, 2002, 7:00 a.m. – 7:00 p.m.
Saturday, September 28, 2002, 7:00 a.m. – 7:00 p.m.

SPECIAL ASSISTANCE

The DOD is committed to making this meeting accessible to all participants. Registrants with special requirements for transportation or hotel accommodations should inform the conference staff in advance of the meeting by calling Mary McConnell at (301) 698-5991 or by sending an e-mail to eohadmin@us-frederick.mail.saic.com.

SPEAKER READY/SLIDE PREVIEW ROOM

The Speaker Ready Room will be located in Room 202A and will be staffed to assist presenters. Speakers are urged to use the equipment in this area to check the order and position of their slides before the sessions in which they are scheduled to appear. This room opens at 3:00 p.m. on Wednesday, September 25 and will be open from 7:00 a.m. to 7:00 p.m. on Thursday, September 26 through Saturday, September 28. *Speakers who bring their presentations on computer disk* should turn in their disk to a staff member at the Speaker Registration booth or in the Speaker Ready Room as soon as they arrive at the meeting and not less than 1 hour prior to their session. *Speakers using slides* should plan to arrive in their assigned meeting room approximately 15 minutes before the session begins to give their slide carousels to the projectionist.

AUDIOVISUAL

Guidance for All Platform Presentations

If you plan to use the LCD projection system, your presentation must be on an IBM PC-compatible disk, CD-ROM, or zip disk and must be in Microsoft PowerPoint format (Office 2000). If you prepare your presentation in Microsoft Office 97, please check for formatting changes by opening it in Office 2000. We will NOT be able to connect your individual computer to the projector. **Please do not bring laptop computers.**

Font recommendations: Arial or Times New Roman for text. Symbol and Monotype Sorts will also be supported. Other fonts will not necessarily be guaranteed and could cause formatting issues.

All 35mm slides should be copies, not originals, in case of loss. Slides should be thumb-spotted by placing a mark in the upper right-hand corner of the slide when it is loaded properly in the slide tray, and numbered in the proper sequence. Use standard horizontal format. Vertical and super slides should be avoided; extra slide carousels are available.

Audiovisual Guidelines for the Keynote, Plenary, and Innovation Sessions

Sessions will be presented in double projection. Both slide projectors and a computer with an LCD projection system will be provided. Speakers must bring either two sets of 35-mm slides or a single disk for this purpose. **OVERHEAD PROJECTORS WILL NOT BE AVAILABLE.** Slides/images will be projected on two separate screens, one on each side of the presenter's platform.

Audiovisual Guidelines for the Interactive, Symposia, and Early A.M. Educational Sessions

A single slide projector and a computer with an LCD projection system will be provided in the Interactive, Symposia, and Early A.M. Educational Sessions. Presenters in these sessions must bring one set of slides or a disk. **OVERHEAD PROJECTORS WILL NOT BE AVAILABLE.**

MESSAGE CENTER

Messages will be posted on the message board (near the Registration Center). Era of Hope conference staff members will be available to answer questions and assist you throughout the meeting.

General Information

CONCURRENT SESSIONS

Symposia

Five or six sessions are scheduled to run concurrently during each Symposia block, and participants may move among Symposia. Presenters are asked to adhere to the strict time schedules. All Symposia presentations will be 10 minutes in length, followed by 5 minutes for questions.

Interactive Sessions


Five Symposia are scheduled to run concurrently. Three to five speakers will act as a panel to stimulate discussion focused on a question. The sessions will 1-1/2 hours with ample time for open discussion.

POSTER SESSIONS

Posters will be exhibited in the Exhibit Hall A1. Poster board assignments and sessions can be found beginning on page 38. An informational kiosk detailing the exact location of each poster will be displayed in the front of the Exhibit Hall A1.

All individuals with invited abstracts are obliged to have their posters assembled and ready for display in the Exhibit Hall A1 by 3:00 p.m. on Thursday, September 26. Poster boards will be available for setup beginning at 1:00 p.m., Wednesday, September 25 and from 7:00 a.m. – 3:00 p.m. on Thursday, September 26. Investigators must be at their posters during the times designated for their Poster Sessions. Within each Poster Session, odd-numbered poster presenters must man their posters during the first hour; even-numbered, during the second hour.

All posters must remain on display until 9:00 p.m. on Saturday, September 28. Materials must be removed by 12:00 noon on Sunday, September 29. Please refer to the diagram below for poster format guidelines.



RECEPTIONS

All registrants are invited and encouraged to attend the following activities that have been planned as additional opportunities to interact with colleagues and make new acquaintances with similar interests.

Welcome Reception—Wednesday, 7:45 p.m.

Era of Hope Reception/Party—Friday, 7:05 p.m.

LUNCH

Lunch will be available during the Poster Session on September 27, 2002. Lunch will also be provided Saturday, September 28 during the session entitled “DOD BCRP New Investigators.” The Food Court on Level I will be available for lunch on Thursday, September 26.

CONFERENCE SERVICES—REGISTRATION AND TRAVEL

SAIC Conference Services—Registration and Travel will be handling registration for the Era of Hope Meeting. If you charge your registration fees to a credit card, please expect to see SAIC Conference Services on your credit card bill/statement, not Era of Hope. If you have questions, please see a registration staff member.

A staff member will be on site to assist attendees traveling on Invitational Travel Orders (ITOs).

TRANSPORTATION

The Orange County Convention Center, Rosen Centre, and Rosen Plaza Hotel are located just 15 minutes from Orlando International Airport. Mears Transportation Group (407-423-5566), the primary provider of shuttle service from the Orlando International Airport, is offering Era of Hope attendees a discount rate of \$20 round-trip. Additional information, including driving directions, can be found on the following websites:

http://www.rosencentre.com/location_orh.html,

<http://www.rosenplaza.com>, and

<http://www.orlandoconvention.com/directions.asp>.

ABSTRACTS ON THE INTERNET

All preregistered participants will receive one copy of the three-volume Proceedings and the Program Booklet.

Additionally, Scientific Abstracts that were provided to conference organizers electronically will be available on the Era of Hope Internet home page: <http://cdmrp.army.mil/bcrp/era>.

AUDIOTAPES

Many of the meeting sessions will be technically reproduced. They will be available for purchase in the registration area.

PRESS RELATIONS

The Press Office is located in the Room 202C. All members of the press should report to the Press Room to register.

Erika Petersen is the Era of Hope Press Manager. All press activities will be managed by Lisa Weiss and Jennifer Goldberg of Cooney Waters.

PHYSICIANS: CONTINUING MEDICAL EDUCATION

This activity is jointly sponsored by the U.S. Army Medical Command and the U.S. Army Medical Research and Materiel Command.

Accreditation Statement

This activity has been planned and implemented in accordance with the essential areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the U.S. Army Medical Command and the U.S. Army Medical Research and Materiel Command. The U.S. Army Medical Command is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The U.S. Army Medical Command designates this educational activity for a maximum of 29.5 credit hours in category 1 credit toward the American Medical Association Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Statement of Need

The planning committee for this activity has determined that an important need exists to provide physicians involved in breast cancer prevention, diagnosis, treatment, or quality of life care with important updates to stay informed of new research and the most current technologies and treatments for breast cancer. This activity is being given because breast cancer is a major health concern affecting one in eight women. The ability to cure breast cancer decreases with disease progression and therefore new detection, diagnostic, therapeutic, and quality of life research is needed to find prevention strategies, new cures, or improve survival and life after breast cancer. This activity will provide a forum in which the research coming from the DOD Breast Cancer Research Program will be presented together with symposia, and plenary presentations by leading experts in oncology and breast cancer consumer advocates, providing the medical community with important updates in the progress toward the above goals.

NURSES: CONTINUING EDUCATION UNITS

The conference organizers have submitted an application for Continuing Education Units for nurses. Details will be provided at registration.

LEARNING OBJECTIVES

At the conclusion of the Era of Hope Meeting, participants should be able to:

- ❖ Describe and discuss recent research results and the innovative approaches that are now being used to study the basic biology, prevention, detection, diagnosis, and treatment of breast cancer, and ways to improve patient quality of life.
- ❖ Comprehend the latest advancements in the genetics and biology of breast cancer; in particular, the role of signal transduction pathways in breast cancer development and progression.
- ❖ Comprehend the latest advancements in the field of breast cancer prevention.
- ❖ Comprehend the latest advancements in identification and characterization of molecular targets that can serve as the basis for individualized breast cancer therapy.
- ❖ Interact and collaborate with breast cancer researchers who work in different scientific and clinical disciplines and network with consumer advocacy organizations.

INTENDED AUDIENCE

This educational activity is designed for civilian and military physicians; nurses; and researchers, especially oncologists, radiologists, pathologists, general/family practitioners, and osteopaths who might be involved in patient diagnosis, treatment, prevention, or post-cancer care. No special prerequisites are required to attend this educational activity.

DISCLOSURE OF FACULTY RELATIONSHIPS

As a provider accredited by the ACCME, it is the policy of the U.S. Army Medical Command to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Disclosure will be made in the handout materials.

DISCLOSURE OF UNLABELED/UNAPPROVED USES OF DRUGS OR DEVICES

NOTICE: In accordance with the ACCME Standards for Commercial Support, the audience is advised that one or more presentations in this continuing medical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices. Disclosure will be made in the handout materials.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

There is no commercial support associated with this educational activity.

Wednesday, September 25, 2002

*Technical Program
at a Glance*

- NOON		
- 1:00 p.m.		Registration <i>Level I</i> Registration Concourse Noon-8:00 p.m.
		Poster Board/ Exhibitor Setup Hall A1 1:00-6:00 p.m.
- 6:00 p.m.		
- 6:15 p.m.		WELCOME AND MOMENT OF SILENCE - Room 304 OPENING KEYNOTE SESSION - Room 304 Past 10 Years: Next 10 Years
- 7:45 p.m.		WELCOME RECEPTION - Level I Foyer
- 9:00 p.m.		

*Technical Program
at a Glance*

Thursday, September 26, 2002

7:00 a.m.	Room 101		Room 102	Room 103
8:00 a.m.	Breast Pathology (Normal, Premalignant, Invasive)	Translational Research: Who, What, When, Where, and How?	Signal Transduction and Cancer: A Primer	
8:10 a.m.	WELCOME AND MOMENT OF SILENCE - Room 304			
8:45 a.m.	KEYNOTE ADDRESS - Room 304			
9:30 a.m.	Rules Determining the Formation of Human Cancer Cells			
9:45 a.m.	PLENARY - Signal Transduction - Room 304			
10:50 a.m.	Break			
11:05 a.m.	PLENARY - Signal Transduction (cont.) - Room 304			
	Break			
	CONCURRENT SYMPOSIUM SESSIONS			
	Room 101	Room 102	Room 103	Room 104
12:35 p.m.	Symp. 1 - Molecular Imaging of Breast Cancer Pathways	Symp. 2 - The Multifaceted Nature of p53	Symp. 3 - Targeted Immunotherapeutic Approaches to Breast Cancer	Symp. 4 - New Approaches to Tyrosine Kinase Growth Factor Receptors
1:45 p.m.	Lunch Break			
3:15 p.m.	Symp. 6 - Novel Therapeutic Approaches I	Symp. 7 - Medical/Surgical Considerations	Symp. 8 - Endocrine Carcinogenesis	Symp. 9 - TGF- β and Breast Cancer
3:30 p.m.	Break			
	CONCURRENT INTERACTIVE SESSIONS			
	Room 101	Room 102	Room 103	Room 104
5:00 p.m.	IS 1. What Can Be Accomplished by Early Detection?	IS 2. How Can We Keep Metastatic Lesions Dormant?	IS 3. Can We Individualize the Treatment of Patients with Breast Cancer Based on Genomic Profiles?	IS 4. The Genomic Revolution: What Is the Impact on Patients?
5:15 p.m.				IS 5. What Evidence Do We Have of Environmental Effects on Breast Cancer?
6:15 p.m.	Break			
6:30 p.m.	INNOVATION SESSION - Room 304			
	The Structure Basis of Tissue-Specificity in Normal and Malignant Breast - Epigenetics Comes of Age			
	Break			
	POSTER SESSION/RECEPTION - Hall A1			
8:30 p.m.	P1 - Oncogenes P2 - Mammary Gland Development P3 - Signal Transduction P4 - Transcription, Translation, and Modification P5 - Genomics and Proteomics	P6 - Endocrine Carcinogenesis P7 - Hormone Receptors P8 - Biomarkers I P9 - Tumor Progression I P10 - Apoptosis	P11 - Tumor Immunology P12 - Lifestyle P13 - Chemoprevention P14 - Nuclear Medicine Imaging	P15 - Computer-Aided Diagnosis P16 - Drug Design and Development I P17 - Radiotherapy P18 - Epidemiology I

Registration Level I
Registration Concourse Begins
7:00 a.m. - 7:00 p.m.

Poster Board/Exhibitor Setup
Hall A1
7:00 a.m. - 3:00 p.m.

*Technical Program
at a Glance*

Friday, September 27, 2002

7:00 a.m.	EARLY A.M. EDUCATIONAL SESSIONS		Registration Level I Registration Concourse Begins 7:00 a.m. - 7:00 p.m.
	Room 101	Room 102	Room 103
8:00 a.m.	Overview of Immunology	How Epidemiologists Do Studies	Why Studying Normal Development Is Important for Understanding Breast Cancer
8:10 a.m.	WELCOME AND MOMENT OF SILENCE - Room 304		
8:45 a.m.	KEYNOTE ADDRESS - Room 304 Breast Cancer Prevention: Provens, Potentials, and Promises		
10:20 a.m.	PLENARY - Room 304 Breast Cancer Prevention		
10:40 a.m.	Break		
	CONCURRENT INTERACTIVE SESSIONS		
	Room 101	Room 102	Room 103
12:10 p.m.	IS 6. What Leads to Hormonal Resistance and How Can We Circumvent It?	IS 7. Does Lifestyle Contribute to Breast Cancer Prevention?	IS 8. How Do We Block DCIS from Becoming Invasive?
12:15 p.m.	IS 9. What Makes A Good Animal Model for Breast Cancer?	IS 10. What Factors Influence Breast Cancer Susceptibility in Pre-Menopausal Women?	
	POSTER SESSION (includes lunch) - Hall A1		
	P19 - Cell Cycle P20 - BRCA1 and BRCA2 Tumor Suppressor Genes P21 - EGF Superfamily P22 - DNA Damage and Repair P23 - Mechanisms of Hormone Action	P24 - Biomarkers II P25 - Tumor Progression II P26 - Adhesion, Motility, and Cell Shape P27 - Proteolysis in Tumor Progression	P28 - Digital Imaging P29 - Ultrasonography P30 - X-Ray Imaging P31 - Drug Design and Development II P32 - Gene Therapy P33 - Immunotherapies P34 - Biobehavioral Sciences and Decision Making P35 - Epidemiology II
2:15 p.m.	Break		
2:30 p.m.	CONCURRENT SYMPOSIA SESSIONS		
	Room 101	Room 102	Room 103
4:00 p.m.	Symp. 11 - Computer-Aided Image Analysis	Symp. 12 - Breast Cancer Survivorship: Ethnic, Cultural, and Social Economic Factors	Symp. 13 - Innovative Breast Cancer Vaccine Strategies
4:15 p.m.	Symp. 14 - Stromal Influences on Breast Cancer	Symp. 15 - DNA Damage, Repair, and Apoptosis	Symp. 16 - Programming Prevention
5:45 p.m.	Symp. 17 - Digital Imaging: Diagnostic Potential and Enhancing Availability	Symp. 18 - Exposure, Lifestyle, and Breast Cancer Etiology	Symp. 19 - Steroid Receptors and Signaling
6:00 p.m.	Symp. 20 - New Approaches to Breast Cancer Metastasis	Symp. 21 - The Role of BRCA Genes in Breast Cancer Development	Symp. 22 - Natural Products for Breast Cancer Therapy
7:00 p.m.	Break		
7:05 p.m.	INNOVATION SESSION - Room 304 Tumor Immunology Update		
9:05 p.m.	ERA OF HOPE RECEPTION - Rosen Centre Pool Deck		

*Technical Program
at a Glance*

Saturday, September 28, 2002

7:00 a.m.	EARLY A.M. EDUCATIONAL SESSIONS			Registration Level I Registration Concourse Begins 7:00 a.m. - 7:00 p.m.
	Room 101	Room 102	Room 103	
8:00 a.m.	Breast Cancer Treatment	Principles, Advantages, and Pitfalls of Array Technologies	Assessment of Technologies for Early Detection of Breast Cancer (IOM Report)	
8:10 a.m.	WELCOME AND MOMENT OF SILENCE - Room 304			
8:45 a.m.	KEYNOTE ADDRESS - Room 304			
9:45 a.m.	Genome-Wide Studies of Gene Expression in Cancer			
10:00 a.m.	INNOVATION SESSION - Room 304			
	Dean Kamen			
	Break			
11:30 a.m.	TOWN HALL - Room 304			
11:50 a.m.	What Are We Missing in Breast Cancer?			
1:10 p.m.	Break			
1:30 p.m.	DOD BCRP NEW INVESTIGATORS' LUNCHEON - Rosen Centre Grand Ballroom C			
	Break			
3:20 p.m.	PLENARY - Room 304			
3:35 p.m.	Targets for Individualized Therapy			
	Break			
	CONCURRENT SYMPOSIA SESSIONS			
5:05 p.m.	Room 101	Room 102	Room 103	Room 105
	Symp. 23 - Innovative Applications in Breast Cancer Imaging	Symp. 24 - Hormonally Regulated Development	Symp. 25 - Impact of Array-Based Technologies on Breast Cancer Research	Symp. 27 - Evolving Targets for Breast Cancer Therapy
5:20 p.m.	Room 101	Room 102	Room 103	Room 105
	Symp. 29 - Novel Approaches for Prognosis/Detection	Symp. 30 - New Genes in Mammary Development	Symp. 31 - Angiogenesis	Symp. 28 - Drugs in Development for Breast Cancer Treatment
6:50 p.m.	Break			Room 106
6:55 p.m.	Break			Symp. 32 - Novel Therapeutic Approaches II
	POSTER SESSION/RECEPTION - Hall A1			Room 105
	P36 - Growth Factors and Cytokines	P43 - Familial and Hereditary Carcinogenesis	P48 - Novel Imaging	Symp. 33 - Genomic Instability and Population Studies
	P37 - Tumor Suppressor Genes	P44 - Genomic Instability	P49 - Magnetic Resonance Imaging	P55 - Drug Resistance
	P38 - TGF-β	P45 - Adhesion Molecules, Extracellular Matrix, and Cytoskeleton in Tumor Progression	P50 - Clinical Management of Breast Cancer	P56 - Community, Consumer, and Clinical Partnerships
	P39 - Tyrosine Kinase Signaling	P46 - Angiogenesis	P51 - Evolving Therapeutic Targets	P57 - Complementary and Alternative Medicine
	P40 - Functional Studies of Biological Molecules	P47 - Nutrition and Neuroceuticals	P52 - Targeted Therapies	P58 - Quality of Life
	P41 - Signaling: Life and Death		P53 - Hormone Therapy and Resistance	P59 - Investment in the Future: Breast Cancer Training Programs
	P42 - Chromosome Structure		P54 - Breast Cancer Vaccines	
8:55 p.m.	Poster Board and Consumer Exhibit Breakdown - Hall A1			
10:00 p.m.	SUNDAY, SEPTEMBER 29, 2002			
7:00 a.m.	Poster Board and Consumer Exhibit Breakdown - Hall A1			
NOON	Poster Board and Consumer Exhibit Breakdown - Hall A1			

WEDNESDAY, SEPTEMBER 25, 2002

12:00 noon -8:00 p.m.	Registration	Level I Registration Concourse
1:00-6:00 p.m.	Poster Board Setup	Hall A1
6:00-6:15 p.m.	WELCOME AND MOMENT OF SILENCE * Lynn M. Matrisian * M. Carolina Hinestrosa * Major General Lester Martinez-Lopez * Colonel Kenneth A. Bertram	Room 304
6:15-7:45 p.m.	OPENING KEYNOTE SESSION - Past 10 Years: Next 10 Years (Introduction by Lynn M. Matrisian) * Frances M. Visco * George W. Sledge, Jr. * Jeffrey M. Trent	Room 304
7:45-9:00 p.m.	Welcome Reception	Level I Foyer

THURSDAY, SEPTEMBER 26, 2002

7:00 a.m.	Registration Open	Level I Registration Concourse
7:00 a.m. - 3:00 p.m.	Poster Board Setup	Hall A1
7:00-8:00 a.m.	Continental Breakfast Available	Room 304 Foyer
7:00-8:00 a.m.	EARLY A.M. EDUCATIONAL SESSIONS	
	Breast Pathology (Normal, Premalignant, Invasive) * Michael F. Press (Introduction by Musa Mayer)	Room 101
	Translational Research: Who, What, When, Where, and How? * William N. Hait (Introduction by Karin D. Noss)	Room 102
	Signal Transduction and Cancer: A Primer * Channing J. Der (Introduction by Betsy Lambert)	Room 103
8:00-8:10 a.m.	WELCOME AND MOMENT OF SILENCE * Rosemary Rosso	Room 304
8:10-8:45 a.m.	KEYNOTE ADDRESS: RULES DETERMINING THE FORMATION OF HUMAN CANCER CELLS * Robert A. Weinberg (Introduction by Patricia S. Steeg)	Room 304
8:45-9:30 a.m.	PLENARY: SIGNAL TRANSDUCTION * (Introduction by Rosemary Rosso)	Room 304
	Consumer Perspective * Patricia Barr	
	A New Paradigm in Breast Cancer Prevention * Jose Russo	
9:30-9:45 a.m.	BREAK	
9:45-10:50 a.m.	PLENARY: SIGNAL TRANSDUCTION (continued) Metastasis Suppressor Genes in Breast Cancer: From Bench to Bedside? * Danny R. Welch Novel Approaches for Inhibiting Tumor Growth and Metastasis Based on Targeting Vascular Addresses in Blood Vessels * Renata Pasqualini Overview: Herceptin Clinical Research and Signal Transduction * Dennis J. Slamon	Room 304

CONCURRENT SYMPOSIA SESSIONS 1-5

- | | |
|-------------------------|--|
| 11:05 a.m. - 12:35 p.m. | <p>SYMPOSIUM 1. MOLECULAR IMAGING OF BREAST CANCER PATHWAYS Room 101</p> <p>* Co-Chair: James P. Basilion and Sandy Walsh</p> <p>Molecular Beacons as an Enhancement of Small Subsurface Breast Cancer Detection</p> <p>* Britton Chance</p> <p>Detection of Malignant Transformation by [¹¹C]Choline-Positron Emission Tomography</p> <p>* Eric O. Aboagye</p> <p>Technetium-99M Anti-EGFRvIII Peptides Selected through Phage Display for the Detection of Breast Cancer</p> <p>* Mary Rusckowski</p> <p>PET Imaging of Estrogen Metabolism in Breast Cancer with [18F]RO41-0960, A Selective COMT Inhibitor</p> <p>* Yu-Shin Ding</p> |
| 11:05 a.m. - 12:35 p.m. | <p>SYMPOSIUM 2. THE MULTIFACETED NATURE OF p53 Room 102</p> <p>* Co-Chairs: Jennifer A. Pietenpol and Christine K. Norton</p> <p>Crystal Structure of the Mouse p53 Core DNA-Binding Domain at 2.7Å Resolution</p> <p>* Ronen Marmorstein</p> <p>Genetic Background Affects Loss of Heterozygosity and Tumor Spectrum in Trp53-Heterozygous Mice</p> <p>* D. Joseph Jerry</p> <p>Mouse Mammary Cancer Models—Mechanisms and Markers</p> <p>* Lawrence A. Donehower</p> <p>The Radiation-Induced p53 – 14-3-3 Interaction Is Critical for p53 Function</p> <p>* Thanos Halazonetis</p> <p>An MDM2-HDAC1 Complex Controls p53 Acetylation and Stability by a Potential Coupling of p53 Acetylation and Ubiquitination</p> <p>* Tso-Pang Yao</p> |
| 11:05 a.m. - 12:35 p.m. | <p>SYMPOSIUM 3. TARGETED IMMUNOTHERAPEUTIC APPROACHES TO BREAST CANCER Room 103</p> <p>* Co-Chairs: Herbert Kim Lyerly and Ana Garcia</p> <p>The Aryl Hydrocarbon (Dioxin) Receptor and Cytochrome P450 1B1 as Targets for Breast Cancer Immunotherapy</p> <p>* David H. Sherr</p> <p>Identification of Helper Peptides of Rat NEU That Can Mediate Partial Therapeutic Antitumor Responses in Breast Tumor-Bearing NEU-Transgenic Mice</p> <p>* Keith L. Knutson</p> <p>Cancer Immunogene Therapy Using MHC-Unrestricted MUC1-Specific T-Cell Receptor</p> <p>* Nehad M. Alajez</p> <p>Recombinant SCFV-Enzyme Fusion Proteins for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)</p> <p>* P. Markus Deckert</p> <p>T-Cell Recognition of Monoclonal Antibodies</p> <p>* Christopher M. Snyder</p> |

CONCURRENT SYMPOSIA SESSIONS 1-5 (continued)

11:05 a.m. - 12:35 p.m.

SYMPOSIUM 4. NEW APPROACHES TO TYROSINE KINASE GROWTH FACTOR RECEPTORS

Room 104

* **Co-Chairs:** Douglas Yee and Ellen Passel

Glucose Metabolism and Breast Cancer Risk: The Ordet Prospective Study

* Paola C. Muti

A Humanized Single Chain Antibody against the Type I IGF Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of Insulin-Like Growth Factor-I

* Deepali Sachdev

Conditional Overexpression of Activated Neu in the Mammary Epithelium of Transgenic Mice Results in Reversible Pulmonary Metastases

* Susan E. Moody

Bispecific Single-Chain FV Molecules That Target HER2/Neu and HER3 Modulate Signal Transduction

* Matthew K. Robinson

Ribozyme Targeting the Novel Fusion Junction of EGFRVIII in Breast Cancer

* Careen K. Tang

11:05 a.m. - 12:35 p.m.

SYMPOSIUM 5. DETERMINANTS OF DRUG RESPONSE IN BREAST CANCER

Room 105

* **Co-Chair:** Katherine A. Kennedy and Venus Ginés

Functional Role of Cysteine Residues in the Extracellular Amino Terminus of Human Multidrug Resistance-Associated Protein 1 (MRP-1)

* Youyun Yang

Expression Profiling of Stress-Treated EMT6 Cells Expressing Mutant I κ B α Protein Reveals Candidate Genes Involved in the Prevention of Stress-Induced Drug Resistance by Inhibition of NF- κ B Activation

* Katherine A. Kennedy

Interaction of UBC9 with Daxx: Implications for the Regulation of the Subcellular Distribution of Daxx and Drug Responsiveness

* Yin-Yuan Mo

Targeting PI3K/AKT for Enhancing Breast Cancer Chemotherapy and Radiotherapy

* Zhen Fan

AND-34/BCAR3 Activates RAC1, CDC42, PAK1, and the Cyclin D1 Promoter

* Adam Lerner

12:35-1:45 p.m.

LUNCH BREAK

CONCURRENT SYMPOSIA SESSIONS 6-10

1:45-3:15 p.m.

SYMPOSIUM 6. NOVEL THERAPEUTIC APPROACHES I

Room 101

* **Co-Chair:** Richard J. Pietras and Mary C. Tunson

Alpha-Particle Emitter (225Ac)-Labeled Herceptin Antibody Targeting of Breast Cancer: Efficacy Versus HER-2/Neu Expression

* George Sgouros

CD34+ Endothelial Progenitors as Cellular Vehicles for Gene Therapy of Breast Cancer

* Jerry L. Blackwell

A Novel Therapy for Breast Cancer by Inducing Hyperacute Rejection

* Charles J. Link

An Endothelial Cell-Based Gene Therapy Approach for Treatment of Breast Cancer Metastases

* John O. Ojeifo

Cell-Free and Cellular Activities of Sequence-Selective Polyamide-Based DNA Alkylating Agents

* Yong-Dong Wang

CONCURRENT SYMPOSIA SESSIONS 6-10 (continued)

1:45-3:15 p.m.	<p>SYMPOSIUM 7. MEDICAL/SURGICAL CONSIDERATIONS</p> <p>* Co-Chairs: Ismail Jatoi and Vernal H. Branch</p> <p>Axillary Dissection and Survival of Women after Breast-Conserving Surgery for Early-Stage Breast Cancer</p> <p>* Xianglin L. Du</p> <p>A Cluster Analytic Approach to Reasons for and against Prophylactic Mastectomy in High-Risk Women</p> <p>* Karen E. Hurley</p> <p>Restoring the Breast Following Mastectomy Via Tissue-Engineering Strategies</p> <p>* Charles W. Patrick, Jr.</p> <p>A Subacute Care Intervention for Short-Stay Breast Cancer Surgery</p> <p>* Gwen K. Wyatt</p> <p>Prediction of Pathologic Fracture Risk in Activities of Daily Living of Patients with Metastatic Breast Carcinoma of the Pelvis and Femur</p> <p>* Nozomu Inoue</p>	Room 102
1:45-3:15 p.m.	<p>SYMPOSIUM 8. ENDOCRINE CARCINOGENESIS</p> <p>* Co-Chairs: Barbara Vonderhaar and Diana Rowden</p> <p>Estrogens Are Carcinogenic in Human Breast Epithelial Cells</p> <p>* Hasan M. Lareef</p> <p>Prolactin and Estrogen Crosstalk in Mammary Tumor Cells</p> <p>* Jennifer H. Gutzman</p> <p>A Transgenic Model of Hormone-Induced Mammary Gland Hyperplasia and Cancer</p> <p>* Ruth A. Keri</p> <p>Age-Related Decline in Serum and Pineal Melatonin Levels in Buffalo Rats</p> <p>* Steven M. Hill</p> <p>Pseudophosphorylated Prolactin (S179D PRL) Inhibits Growth and Promotes Differentiation in the Rat Mammary Gland</p> <p>* Ameae M. Walker</p>	Room 103
1:45-3:15 p.m.	<p>SYMPOSIUM 9. TGF-β AND BREAST CANCER</p> <p>* Co-Chairs: Carlos L. Arteaga and Mary A. Elliott</p> <p>Autocrine TGF-β Signaling Mediates SMAD-Independent Motility in Human Breast Cancer Cells</p> <p>* Nancy Dumont</p> <p>The Influence of Stromal-Transforming Growth Factor-β Receptor Signaling on Mouse Mammary Neoplasia</p> <p>* Michael R. Crowley</p> <p>Transforming Growth Factor-β Stimulates Parathyroid Hormone-Related Protein and Osteolytic Metastases Via SMAD and Mitogen-Activated Protein Kinase Signaling Pathways</p> <p>* Sanna-Maria Kakonen</p> <p>Transforming Growth Factor-β1 Regulates Radiation-Induced Apoptosis and p53 Response</p> <p>* Maria J. Pajares</p> <p>Targeting the Transforming Growth Factor-β Type I Receptor Kinase as a Potential Novel Treatment for Breast Cancer</p> <p>* Michael Reiss</p>	Room 104

CONCURRENT SYMPOSIA SESSIONS 6-10 (continued)		
1:45-3:15 p.m.	<p>SYMPOSIUM 10. BREAST CANCER THERAPY: TARGETING CELL SIGNALING</p> <p>* Co-Chairs: Douglas Yee and Connie Rufenbarger</p> <p>APAB Mediates AKT Survival Signal: Implications in Chemoresistance in Breast Cancer</p> <p>* Zeng-Qiang Yuan</p> <p>Phosphorylation of Tyrosine-15 of P34CDC2 by ERBB2 Inhibits P34CDC2 Activation and Is Involved in Resistance to Taxol-Induced Apoptosis</p> <p>* Dihua Yu</p> <p>TIG3- A Retinoid-Responsive Class II Tumor Suppressor Protein That Inhibits Breast Cancer Cell Proliferation</p> <p>* Richard L. Eckert</p> <p>15-Deoxy-Delta-12,14-Prostaglandin J2 and PPARG: Mechanisms of Action and Potential Therapeutic Targets for the Treatment and Prevention of Breast Cancer</p> <p>* Carl E. Clay</p> <p>Structure-Based Design of ERBB-2 Selective Small Molecule Kinase Inhibitors</p> <p>* Shaomeng Wang</p>	Room 105
3:15-3:30 p.m.	BREAK	
CONCURRENT INTERACTIVE SESSIONS 1-5		
3:30-5:00 p.m.	<p>IS 1. WHAT CAN BE ACCOMPLISHED BY EARLY DETECTION?</p> <p>* Co-Chairs: Abram Recht and M. Carolina Hinestrosa</p> <p>Psychosocial Aspects of Breast Cancer Diagnosis</p> <p>* Cathie Ragovin</p> <p>Much Data, Few Answers: The History of Mammography</p> <p>* Barron Lerner</p> <p>The Role of Biomarkers in Screening and Early Detection of Breast Cancer</p> <p>* Nicole Urban</p> <p>Impact of Molecular Profiling on Molecular Imaging of Breast Cancer</p> <p>* James P. Basilion</p>	Room 101
3:30-5:00 p.m.	<p>IS 2. HOW CAN WE KEEP METASTATIC LESIONS DORMANT?</p> <p>* Co-Chairs: Lynn M. Matrisian and Liz Lostumbo</p> <p>Do Single Cells Constitute a Metastatic Lesion?</p> <p>* Danny R. Welch</p> <p>Tumor Dormancy and Growth Regulation of Metastatic Cells</p> <p>* Ann F. Chambers</p> <p>Clinical Strategies against Metastatic Colonization</p> <p>* Patricia S. Steeg</p>	Room 102
3:30-5:00 p.m.	<p>IS 3. CAN WE INDIVIDUALIZE THE TREATMENT OF PATIENTS WITH BREAST CANCER BASED ON GENOMIC PROFILES?</p> <p>* Co-Chairs: William N. Hait and Musa Mayer</p> <p>How We Might Envision the Individualization of Breast Cancer Therapy—Present and Future</p> <p>* William N. Hait</p> <p>How Can Drugs Be Developed Based on Genomic Profiling of Tumors?</p> <p>* David Parkinson</p> <p>How Can the Genetic Background of the Patient Be Used to Optimize the Use of Cancer Treatments?</p> <p>* Mark J. Ratain</p>	Room 110A

CONCURRENT INTERACTIVE SESSIONS 1-5 (continued)

3:30-5:00 p.m.	<p>IS 4. THE GENOMIC REVOLUTION: WHAT IS THE IMPACT ON PATIENTS? * Co-Chairs: Jeffrey M. Trent and Kathleen Zeitz</p>	Room 110B
3:30-5:00 p.m.	<p>IS 5. WHAT EVIDENCE DO WE HAVE OF ENVIRONMENTAL EFFECTS ON BREAST CANCER? * Co-Chairs: Leslie Bernstein and Rosemary Rosso</p> <p>Does Occupational Exposure to Radiation Increase Breast Cancer Risk: How High Are Current Exposures? * John D. Boice, Jr.</p> <p>Organochlorines and Breast Cancer Risk - Old News or New Challenges? * Kirsten Moysich</p> <p>Current Evidence on Electromagnetic Fields and Breast Cancer * David Savitz</p> <p>Does Working the Night Shift Increase Your Risk of Breast Cancer? * Richard G. Stevens</p>	Room 103
5:00-5:15 p.m.	BREAK	
5:15-6:15 p.m.	<p>INNOVATION SESSION: THE STRUCTURE BASIS OF TISSUE-SPECIFICITY IN NORMAL AND MALIGNANT BREAST—EPIGENETICS COMES OF AGE * Mina J. Bissell (Introduction by Patricia S. Steeg)</p>	Room 304
6:15-6:30 p.m.	BREAK	
6:30-8:30 p.m.	<p>POSTER SESSION/RECEPTION</p> <p>P1 - Oncogenes P2 - Mammary Gland Development P3 - Signal Transduction P4 - Transcription, Translation, and Modification P5 - Genomics and Proteomics P6 - Endocrine Carcinogenesis P7 - Hormone Receptors P8 - Biomarkers I P9 - Tumor Progression I P10 - Apoptosis P11 - Tumor Immunology P12 - Lifestyle P13 - Chemoprevention P14 - Nuclear Medicine Imaging P15 - Computer-Aided Diagnosis P16 - Drug Design and Development I P17 - Radiotherapy P18 - Epidemiology I</p>	Hall A1

FRIDAY, SEPTEMBER 27, 2002

7:00 a.m.	Registration Open	Level I Registration Concourse
7:00-8:00 a.m.	Continental Breakfast Available	Room 304 Foyer
7:00-8:00 a.m.	EARLY A.M. EDUCATIONAL SESSIONS	
	Overview of Immunology	Room 101
	* Mary Lenora Disis (Introduction by Ana Garcia)	
	How Epidemiologists Do Studies	Room 102
	* Kay Dickersin (Introduction by Diane Z. Chase)	
	Why Studying Normal Development Is Important for Understanding Breast Cancer	Room 103
	* Jeffrey M. Rosen (Introduction by Brian R. Shappell)	
8:00-8:10 a.m.	WELCOME AND MOMENT OF SILENCE	Room 304
	* Leslie Bernstein and Ngina Lythcott	
8:10-8:45 a.m.	KEYNOTE ADDRESS: BREAST CANCER PREVENTION: PROVENS, POTENTIALS, AND PROMISES	Room 304
	* Thomas A. Sellers (Introduction by Mary Lenora Disis)	
8:45-10:20 a.m.	PLENARY: BREAST CANCER PREVENTION	Room 304
	* (Introduction by Marlene C. McCarthy)	
	Consumer Perspective	
	* Ngina Lythcott	
	Breast Cancer Risk Prediction: What Is It Worth?	
	* Beverly Rockhill	
	Behavioral Contributions to Breast Cancer Prevention	
	* Suzanne M. Miller	
	New Approaches to Chemoprevention of Breast Cancer	
	* Michael B. Sporn	
10:20-10:40 a.m.	BREAK	
	CONCURRENT INTERACTIVE SESSIONS 6-10	
10:40 a.m.-12:10 p.m.	IS 6. WHAT LEADS TO HORMONAL RESISTANCE AND HOW CAN WE CIRCUMVENT IT?	Room 101
	* Co-Chairs: George W. Sledge, Jr. and Marlene C. McCarthy	
	Targeting the Epidermal Growth Factor/HER2 Receptor Pathway as a Strategy to Prevent Endocrine Therapy Resistance in Breast Cancer	
	* Suleiman Alfred Massarweh	
	Alterations in Growth Factor Signaling Pathways and Resistance to Anti-Hormonal Therapy	
	* Julia M. W. Gee	
	Novel Hormonal Therapies and Their Role in the Post-Tamoxifen Era	
	* Anthony Howell	
10:40 a.m.-12:10 p.m.	IS 7. DOES LIFESTYLE CONTRIBUTE TO BREAST CANCER PREVENTION?	Room 102
	* Co-Chairs: Leslie Bernstein and Vernal H. Branch	
	Is Lifestyle a Viable Target for Breast Cancer?	
	* Leslie Bernstein	
	Does Fruit and Vegetable Intake Help Prevent Breast Cancer?	
	* Diane F. Birt	
	Is There Sufficient Evidence to Correlate Exercise and Breast Cancer?	
	* Graham A. Colditz	
	Practical Approaches to Lower Risk	
	* Thomas A. Sellers	

CONCURRENT INTERACTIVE SESSIONS 6-10 (continued)		
10:40 a.m.-12:10 p.m.	<p>IS 8. HOW DO WE BLOCK DCIS FROM BECOMING INVASIVE? * Co-Chairs: Patricia S. Steeg and Carol Matyka</p> <p>Duct Carcinoma in situ as a Model for Preinvasive Disease: A Thirty-Year Perspective * Michael Lagios</p> <p>DCIS Diagnosis and Treatment: A Patient Perspective * Carol Matyka</p> <p>Gene Expression Profiling of Premalignant, Preinvasive, and Invasive Breast Cancer * Dennis C. Sgroi</p> <p>Proteomics of DCIS * Patricia S. Steeg</p>	Room 103
10:40 a.m.-12:10 p.m.	<p>IS 9. WHAT MAKES A GOOD ANIMAL MODEL FOR BREAST CANCER? * Co-Chairs: Lynn M. Matrisian and Christine K. Norton</p> <p>Using Genetically Engineered Mice as Models for Different Stages of Breast Cancer * Jeffrey M. Rosen</p> <p>What Can We Learn from Rat Models for Breast Cancer? * Michael Gould</p> <p>Are Mouse Models of Breast Cancer Good Enough? * Roy Jensen</p>	Room 104
10:40 a.m.-12:10 p.m.	<p>IS 10. WHAT FACTORS INFLUENCE BREAST CANCER SUSCEPTIBILITY IN PRE-MENOPAUSAL WOMEN? * Co-Chairs: William N. Hait and Joy Simha</p> <p>Epidemiology Overview: Burden of Disease for Pre-Menopausal Women Kay Dickersin</p> <p>Why Study Risk in Younger Women? Influence of Early Life and Susceptible Subgroups * Richard G. Stevens</p> <p>Pre-Menopausal Breast Cancer in Relation to Mammary Gland Development * Irma H. Russo</p> <p>The Impact of Genetics on the Development of Pre-Menopausal Breast Cancer * Deborah Toppmeyer</p>	Room 105
12:15-2:15 p.m.	<p>POSTER SESSION (includes lunch)</p> <p>P19 - Cell Cycle P20 - BRCA1 and BRCA2 Tumor Suppressor Genes P21 - EGF Superfamily P22 - DNA Damage and Repair P23 - Mechanisms of Hormone Action P24 - Biomarkers II P25 - Tumor Progression II P26 - Adhesion, Motility, and Cell Shape P27 - Proteolysis in Tumor Progression P28 - Digital Imaging P29 - Ultrasonography P30 - X-Ray Imaging P31 - Drug Design and Development II P32 - Gene Therapy P33 - Immunotherapies P34 - Biobehavioral Sciences and Decision Making P35 - Epidemiology II</p>	Hall A1
2:15-2:30 p.m.	BREAK	

CONCURRENT SYMPOSIA SESSIONS 11-16

2:30-4:00 p.m.	<p>SYMPOSIUM 11. COMPUTER-AIDED IMAGE ANALYSIS</p> <p>* Co-Chairs: David Gur and Helen Schiff</p> <p>A New Model for the Estimation of Breast Cancer Risk</p> <p>* Maryellen Giger</p> <p>Computerized Analysis of Solid Masses in 3D Ultrasound Volumes for Breast Cancer Diagnosis</p> <p>* Berkman Sahiner</p> <p>Database-Aided Detection and Diagnosis of Mammograms</p> <p>* Jack Sklansky</p> <p>Computer-Aided Diagnosis of Malignant and Benign Breast Lesions in Mammograms</p> <p>* Yulei Jiang</p> <p>Automated Registration and Characterization Techniques for Interval Change Analysis in Mammography</p> <p>* Lubomir M. Hadjiiski</p>	Room 101
2:30-4:00 p.m.	<p>SYMPOSIUM 12. BREAST CANCER SURVIVORSHIP: ETHNIC, CULTURAL, AND SOCIAL ECONOMIC FACTORS</p> <p>* Co-Chairs: William H. Redd and Ngina Lythcott</p> <p>Race Differences in Breast Cancer Survival</p> <p>* Beth A. Jones</p> <p>Ethnic Differences in Breast Cancer Prognosis and Short-Term Survival among New Mexico Women</p> <p>* Diane D. Crumley</p> <p>Racial Disparity in the Quality of Adjuvant Chemotherapy for Breast Cancer</p> <p>* Jennifer J. Griggs</p> <p>Effect of Socioeconomic and Cultural Factors on Breast Cancer Survival</p> <p>* Donald R. Lannin</p> <p>Identifying Quality of Life and Psychosocial Risk Factors and Their Sociocultural Mediators in African American, Asian, Latino, and White Breast Cancer Survivors (BCS)</p> <p>* Kimlin Tam Ashing-Giwa</p>	Room 102
2:30-4:00 p.m.	<p>SYMPOSIUM 13. INNOVATIVE BREAST CANCER VACCINE STRATEGIES</p> <p>* Co-Chairs: Keith L. Knutson and Cathie Ragovin</p> <p>NMR Studies of the Humoral Immune Recognition of a Glycopeptide Breast Cancer Antigen: Significance to Vaccine Design</p> <p>* A. Patricia Campbell</p> <p>Detection of "Superagonist" Mimics of Breast Cancer Mucin Epitopes</p> <p>* Malcolm S. Mitchell</p> <p>DNA Vaccination against HER2/NEU Using Alphavirus-Based Vectors</p> <p>* Lawrence B. Lachman</p> <p>Successful Therapy of Metastatic Mammary Cancer Using Tumor Vaccines in Mixed Allogeneic Bone Marrow Chimeras</p> <p>* Ephraim J. Fuchs</p> <p>Genetic Immunization for Breast Cancer</p> <p>* Max W. Sung</p>	Room 103

CONCURRENT SYMPOSIA SESSIONS 11-16 (continued)

2:30-4:00 p.m.	<p>SYMPOSIUM 14. STROMAL INFLUENCES ON BREAST CANCER * Co-Chair: Arthur M. Mercurio and Sylvia G. Rickard</p> <p>Breast Cancer Behavior Is Linked to Expression of Fibronectin and Tenascin and the Integrins AVB1, AVB6, and A5B1 * Valerie M. Weaver</p> <p>A Novel Method for Studying Mammary Stromal Effects on Human Epithelial Differentiation and Function * Hema R. Parmar</p> <p>Map Kinase Activation of ETS2 in the Mammary Stroma Regulates Tumor Progression * Robert G. Oshima</p> <p>Mammary Gland Stroma Contributes to Epithelial Cell Neoplasia * Maricel V. Maffini</p>	Room 104
2:30-4:00 p.m.	<p>SYMPOSIUM 15. DNA DAMAGE, REPAIR, AND APOPTOSIS * Co-Chairs: Geoffrey M. Wahl and Jane Reese-Coulbourne</p> <p>Inhibition of Diethylstilbestrol-Induced Mitochondrial DNA Adducts by Diallyl Sulfide * Ronald D. Thomas</p> <p>Transduction of Exonuclease III into Mitochondria of Breast Cancer Cells and Its Effect on Mitochondrial DNA Repair * Inna N. Shokolenko</p> <p>Phosphorylation of CEACAM1-4S Induces Lumen Formation by Apoptosis in Transfected MCF-7 Mammary Carcinoma Cells * Julia Kirshner</p> <p>Novel Small-Molecule Inhibitors of BCL-2 as Potential Novel Therapy for the Treatment of Breast Cancer * Shaomeng Wang</p> <p>Profiling Apoptosis-Mediating Proteins in Breast Cancers from Korean Women * Edward W. Gabrielson</p>	Room 105
2:30-4:00 p.m.	<p>SYMPOSIUM 16. PROGRAMMING PREVENTION * Co-Chairs: Henry J. Thompson and Bettye L. Green</p> <p>Sexual Maturation, Mammary Gland Maturation, and Risk for Breast Cancer Are Differentially Affected by Whole Foods Compared to Preformed Vitamin A in the SD Rat * Pepper J. Schedin</p> <p>Genistein Programming against Breast Cancer * Coral A. Lamartiniere</p> <p>Intermediate Molecular Biomarkers for the Protective Effect of Pregnancy against Breast Cancer * Melanie R. Ginger</p> <p>Parity-Induced Changes in Mammary Gene Expression * Lewis A. Chodosh</p> <p>Intraductal Ablation or Differentiation of Mammary Epithelium as a Mode of Prevention of Breast Cancer * Mustafa Vali</p>	Room 106
4:00-4:15 p.m.	BREAK	

CONCURRENT SYMPOSIA SESSIONS 17-22

4:15-5:45 p.m.	<p>SYMPOSIUM 17. DIGITAL IMAGING: DIAGNOSTIC POTENTIAL AND ENHANCING AVAILABILITY</p> <p>* Co-Chairs: Maryellen Giger and Dale Eastman</p> <p>Automated Stereo Spot Mammography for Improved Imaging of Dense Breasts</p> <p>* Mitchell M. Goodsitt</p> <p>Access for Women with Disabilities</p> <p>* Kathleen McCarthy-Barnett</p> <p>Design of a Multisite, Telephone-Based Telemammography System</p> <p>* David Gur</p> <p>Preliminary Findings of the National Native American Cancer Survivors' Support Network</p> <p>* Alisa Gilbert</p>	Room 101
4:15-5:45 p.m.	<p>SYMPOSIUM 18. EXPOSURE, LIFESTYLE, AND BREAST CANCER ETIOLOGY</p> <p>* Co-Chair: Jeffrey Berenberg and Claudia E. Wayne</p> <p>Soyfood Intake, Insulin-Like Growth Factor-I, and Breast Cancer Risk</p> <p>* Maureen Sanderson</p> <p>Influence of Specific Food Groups and Weight on Breast Cancer Risk in Postmenopausal African American Women</p> <p>* Tanya Agurs-Collins</p> <p>Prospective Study of Estrogens During Pregnancy and Risk of Breast Cancer</p> <p>* Pentti K. Siiteri</p> <p>Lifetime Physical Activity and Breast Cancer Risk in a Multiethnic Population: The San Francisco Bay Area Breast Cancer Study</p> <p>* Esther M. John</p> <p>Proximity of Residence at Birth to Potential Radiation Exposure and Risk of Breast Cancer</p> <p>* Jo Freudenheim</p>	Room 102
4:15-5:45 p.m.	<p>SYMPOSIUM 19. STEROID RECEPTORS AND SIGNALING</p> <p>* Co-Chairs: Janardan K. Reddy and Eve Sánchez Silver</p> <p>Structural and Molecular Determinants of Ligand Discrimination between Estrogen Receptors α and β</p> <p>* Geoffrey L. Greene</p> <p>Membrane-Associated Estrogen Receptors Localize to Caveola-Related Domains and Contribute to Growth Regulation of Breast Cancer Cells</p> <p>* Richard J. Pietras</p> <p>Identification and Characterization of Novel ER-β-Sparing Antiprogestins</p> <p>* Ganesan Sathya</p> <p>New Transcriptional Coregulators of Progesterone Receptors</p> <p>* Jennifer K. Richer</p> <p>Impact of C-NEU/ErbB2 on Progesterone Receptor Expression in Mammary Ductal Epithelial Cells</p> <p>* Gopalan Shyamala</p>	Room 103

CONCURRENT SYMPOSIA SESSIONS 17-22 (continued)		
4:15-5:45 p.m.	SYMPOSIUM 20. NEW APPROACHES TO BREAST CANCER METASTASIS * Co-Chairs: Ann Chambers and Musa Mayer Analysis of Metastasis Using in vivo Imaging and Gene Expression Analysis Using cDNA Microarrays on Small Numbers of Chemotactic and Invasive Cells Collected from Primary Mammary Tumors * Weigang Wang Integrin Activation in Breast Cancer Metastasis * Brunhilde Felding-Habermann Genes Involved in Breast Cancer Metastasis to Bone and Breast Tumor Cell-Stroma Cell Interactions in the Bone * Robin L. Anderson CU-64-DOTA-CTTHWGFTLC: A Radiolabeled Gelatinase Inhibitor for PET Imaging of Metastatic Breast Cancer * Carolyn J. Anderson Computer-Aided Early Detection of Axillary Metastases with Dynamic PET * Xiaoli Yu	Room 104
4:15-5:45 p.m.	SYMPOSIUM 21. THE ROLE OF BRCA GENES IN BREAST CANCER DEVELOPMENT * Co-Chairs: Wen-Hwa Lee and Brian R. Shappell Modifiers of Penetrance in BRCA1 Mutation Carriers * Katherine L. Nathanson Breast Cancer Susceptibility Genes and Genomic Instability * Phang-Lang Chen BRCA1-Mediated Large-Scale Chromatin Unfolding and Transcriptional Regulation * Rong Li Cancer Susceptibility of Mice with a Homozygous Deletion in the COOH-Terminal Domain of the BRCA2 Gene with or without a Germline p53 Mutation * Kimberly A. McAllister Development of Chemical and Genetic Synthetic Lethality Screens in BRCA1-Deficient Cultured Tumor Cells: A Novel Approach to Anticancer Drug Discovery * Dan Canaani	Room 105
4:15-5:45 p.m.	SYMPOSIUM 22. NATURAL PRODUCTS FOR BREAST CANCER THERAPY * Co-Chairs: John J. McCormack and Diana Chingos Effects of St. John's Wort and Vitamin E on Breast Cancer Chemotherapeutic Agents * Richard F. Branda Natural Products That Target Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-Gamma) in Breast Tumor Cells * Dale G. Nagle Conjugated Linoleic Acid Modulation of Mammary Stromal Differentiation Contributes to Its Chemopreventive Activity in Mammary Carcinogenesis * Margot M. Ip Dietary Antioxidant Vitamins C and E and Breast Cancer Survival * Lenore Arab Antiproliferative Effects of Indole-3-Carbinol-Based Compounds on Human Breast Cancer Cells * Vaishali Kerekatte	Room 106
5:45-6:00 p.m.	BREAK	
6:00-7:00 p.m.	INNOVATION SESSION: TUMOR IMMUNOLOGY UPDATE * Mary Lenora Disis (Introduction by Leslie Bernstein)	Room 304
7:05-9:05 p.m.	ERA OF HOPE RECEPTION	Rosen Centre Pool Deck

SATURDAY, SEPTEMBER 28, 2002

7:00 a.m.	Registration Open	Level I Registration Concourse
7:00-8:00 a.m.	Continental Breakfast Available	Room 304 Foyer
7:00-8:00 a.m.	EARLY A.M. EDUCATIONAL SESSIONS	
	Breast Cancer Treatment	Room 101
	* George W. Sledge, Jr. (Introduction by Bettye Green)	
	Principles, Advantages, and Pitfalls of Array Technologies	Room 102
	* Paul S. Meltzer (Introduction by Diane Z. Chase)	
	Assessment of Technologies for the Early Detection of Breast Cancer – Conclusions and Recommendations from the IOM Report	Room 103
	* Sharyl Nass (Introduction by Wish Martin)	
8:00-8:10 a.m.	WELCOME AND MOMENT OF SILENCE	Room 304
	* Frances M. Visco	
8:10-8:45 a.m.	KEYNOTE ADDRESS: GENOME-WIDE STUDIES OF GENE EXPRESSION IN CANCER	Room 304
	* David Botstein (Introduction by William N. Hait)	
8:45-9:45 a.m.	INNOVATION SESSION	Room 304
	* Dean Kamen (Introduction by Anna D. Barker)	
9:45-10:00 a.m.	BREAK	
10:00-11:30 a.m.	TOWN HALL: WHAT ARE WE MISSING IN BREAST CANCER?	Room 304
	* Moderator: Anna D. Barker	
	* Facilitator: Alex Valadez	
	* Panel Members:	
	- Mina J. Bissell	
	- David Botstein	
	- Dennis J. Slamon	
	- Frances M. Visco	
11:30-11:50 a.m.	BREAK	
11:50 a.m.-1:10 p.m.	DOD BCRP NEW INVESTIGATORS' LUNCHEON	Rosen Centre Grand Ballroom C
	* Co-Chairs: Patricia C. Modrow and M. Carolina Hinestroza	
	Identification of Estrogen-Responsive Genes and Their Role in Breast Cancer	
	* Malavika G. Ghosh	
	Evaluating Two Different Minibodies, (SCFV-CH3)₂, against HER2/NEU for Imaging of Breast Cancer	
	* Tove Olafsen	
	Application of Imaging Approaches to the Monitoring of Targeted Therapies of Breast Cancer	
	* Bond Almand	
	SAHR, A New Marker of Senescence	
	* Masashi Narita	
	A Unique Type II Topoisomerase Mutant That Is Hypersensitive to a Broad Range of Cleavage-Inducing Antitumor Agents	
	* Erin K. O'Reilly	
	Dissecting the Mechanisms of T-Cell Tolerance for More Effective Breast Cancer Vaccine Development	
	* Anne M. Ercolini	
1:10-1:30 p.m.	BREAK	

1:30-3:20 p.m.	<p>PLENARY: TARGETS FOR INDIVIDUALIZED THERAPY * (Introduction by M. Carolina Hinestroza)</p> <p>Consumer Perspective * Christine A. Brunswick</p> <p>RNA Expression Profiling to Determine Which Breast Cancer Patients Need Adjuvant Systemic Therapy * Sjoerd Rodenhuis</p> <p>Anti-Angiogenic Strategies Based on Tetrathiomolybdate-Induced Copper Deficiency * Sofia D. Merajver</p> <p>Anti-Angiogenesis and Oncogenes: A Tailored Designed Therapy * Luisa Iruela-Arispe</p> <p>The Promise and Reality of Biomarkers: Hopeful but Cautionary Tales * Donald A. Berry</p>	Room 304
3:20-3:35 p.m.	<p>BREAK</p> <hr/> <p>CONCURRENT SYMPOSIA SESSIONS 23-28</p> <hr/>	
3:35-5:05 p.m.	<p>SYMPOSIUM 23. INNOVATIVE APPLICATIONS IN BREAST CANCER IMAGING * Co-Chairs: Thomas L. Chenevert and Arlyne Draper</p> <p>MRI for Monitoring Treatment and Predicting Disease Recurrence * Savannah C. Partridge</p> <p>Dynamic Functional Mammography: A Non-Ionizing Imaging Technique for Early Detection of Breast Cancer * Suzanne J. Smith</p> <p>Detection and Diagnosis of Early Breast Tumors with Optoacoustic Tomography * Alexander A. Oraevsky</p> <p>Preliminary Results of a New Method of 3D Ultrasound Contrast Agent Mapping of Vascular Anomalies for Characterization of Breast Masses * Gerald L. LeCarpentier</p> <p>Dual-Modality Imaging System for Breast Cancer Research * Mark B. Williams</p>	Room 101
3:35-5:05 p.m.	<p>SYMPOSIUM 24. HORMONALLY REGULATED DEVELOPMENT * Co-Chairs: William J. Muller and Karin D. Noss</p> <p>c-Src-Specific Activation of the Estrogen Receptor Is Required for Normal Mammary Gland Development * William J. Muller</p> <p>Modulation of Estrogen Receptor Function by BRCA1 * Thomas G. Boyer</p> <p>Extracellular Matrix Regulation of Estrogen Receptors in Mouse Mammary Cells * Virginia Novaro</p> <p>Transcript Profiling of Prolactin-Dependent Models of Mammary Development Reveals Genes Important for Lobuloalveolar Development * Jessica Harris</p> <p>Neu and Androgen Receptor Regulate Cellular Fate in the Mammary Gland * Michael N. Gould</p>	Room 102

CONCURRENT SYMPOSIA SESSIONS 23-28 (continued)		
3:35-5:05 p.m.	<p>SYMPOSIUM 25. IMPACT OF ARRAY-BASED TECHNOLOGIES ON BREAST CANCER RESEARCH</p> <p>* Co-Chairs: Joe Gray and Nancy Ryan</p> <p>Genomic Copy Number Aberrations in Mouse Primary Breast Tumors Identified Using Array-Based Comparative Genomic Hybridization</p> <p>* Graeme Hodgson</p> <p>Gene Expression Profiles for Docetaxel Chemosensitivity</p> <p>* Jenny Chee Ning Chang</p> <p>EGR1 Target Genes in Breast Cancer Detected Using Promoter Arrays</p> <p>* Ian de Belle</p> <p>Gene Targets in Breast Tumor Cells That Mediate Phenotypic Reversion of Transformation</p> <p>* Gabriele E. Foos</p> <p>Detection of Breast Cancer by Identification of Hypermethylated DNA Is Limited by Non-Specific Methylation in Normal Cells</p> <p>* Edward W. Gabrielson</p>	Room 103
3:35-5:05 p.m.	<p>SYMPOSIUM 26. DENDRITIC CELL VACCINES</p> <p>* Co-Chairs: Mary Lenora Disis and Christine B. Carpenter</p> <p>Prevention of Spontaneous Mammary Carcinoma by Immunization with Dendritic/Tumor Fusion Cells</p> <p>* Jianlin Gong</p> <p>Microtubules Participate in Cytokine-Induced Myeloid Dendritic Cell Differentiation, Maturation, and Function</p> <p>* Shuang Wei</p> <p>Intratumoral Administration of Adeno CD40L or Dendritic Cells Overexpressing CD40L Elicited Effective Antitumor Immunity in Mice</p> <p>* Zoya R. Yurkovetsky</p> <p>The Use of Venezuelan Equine Encephalitis Replicons Encoding the Her-2/neu Tumor-Associated Antigen for the Induction of Protective Cellular Immune Responses</p> <p>* Brian Long</p> <p>Combined Use of Antisense Gene Transfer and TGF-β Neutralizing Antibody Increases the Effectiveness of Dendritic Cell Vaccines in Treating Established Mammary Tumors</p> <p>* Emmanuel T. Akporiaye</p>	Room 106
3:35-5:05 p.m.	<p>SYMPOSIUM 27. EVOLVING TARGETS FOR BREAST CANCER THERAPY</p> <p>* Co-Chairs: Jose Russo and Diana Chingos</p> <p>The Proteasome as a Target for Breast Cancer Therapy</p> <p>* Robert Z. Orłowski</p> <p>Proteolytic Instability in Breast Cancer Cells</p> <p>* Maria E. Gaczynska</p> <p>Restoration of Dystroglycan Function as a Novel Target for Cancer Therapy</p> <p>* John Muschler</p> <p>Rational Structure-Based Design of Anti-Breast-Cancer Drugs Targeting the Erb-B Family of Receptor Tyrosine Kinases</p> <p>* Ruben A. Abagyan</p> <p>Characterization of the Biologically Essential Domain in the N-Terminus of the Human Telomerase Catalytic Subunit</p> <p>* Blaine N. Armbruster</p>	Room 104

CONCURRENT SYMPOSIA SESSIONS 23-28 (continued)

3:35-5:05 p.m.	SYMPOSIUM 28. DRUGS IN DEVELOPMENT FOR BREAST CANCER TREATMENT * Co-Chairs: Elaine M. Kaime and Marlene C. McCarthy The Schweinfurthins: New Leads for Breast Cancer Therapy * David F. Wiemer Therapeutic Actions of Novel Polyamine Analogues against Breast Cancer * Nancy E. Davidson Novel Breast Tumor Differentiation Agents * Jeannine S. Strobl Using GSTP1-1 to Generate Cytotoxic Exocyclic Enones in MDR Breast Tumors * Donald J. Creighton National Breast Cancer Coalition Fund's Clinical Trial Initiative * Christine Brunswick	Room 105
----------------	--	----------

5:05-5:20 p.m. BREAK

CONCURRENT SYMPOSIA SESSIONS 29-34

5:20-6:50 p.m.	SYMPOSIUM 29. NOVEL APPROACHES FOR PROGNOSIS/DETECTION * Co-Chairs: Graham Casey and Kathleen Harris MRS Analysis of Primary Breast Lesions Provides Nodal Status: Translation into the Clinic * Cynthia Lean Early Detection of Breast Cancer by Molecular Analysis of Ductal Lavage Fluid * Saraswati Sukumar Analysis of NES1/Kallikrein 10 MRNA Expression by in situ Hybridization, a Novel Marker for Breast Cancer * Vimla Band Development of a Microarray ELISA for Measuring Cancer Biomarkers * Richard C. Zangar	Room 101
5:20-6:50 p.m.	SYMPOSIUM 30. NEW GENES IN MAMMARY DEVELOPMENT * Co-Chair: Jeffrey M. Rosen and Elaine S. Hill The EDD Gene Is Amplified and Overexpressed in Breast Cancer and Is Essential in Mammalian Development * Colin K. W. Watts Regulation of Mammary Epithelial Cell Growth by CCAAT/Enhancer Binding Protein (C/EBP) β * Linda Sealy Overexpression of Upstream Stimulatory Factor 2 (USF-2) in the Mammary Gland Reduces the Growth of Myc-Dependent Tumors * Darryl L. Hadsell Galanin Regulation of Mammary Lobuloalveolar Development * Matthew J. Naylor Matrix Metalloproteinases Have Distinct Roles in Mammary Gland Branching Morphogenesis * Bryony S. Wiseman	Room 102

CONCURRENT SYMPOSIA SESSIONS 29-34 (continued)

5:20-6:50 p.m.	<p>SYMPOSIUM 31. ANGIOGENESIS</p> <p>* Co-Chairs: Luisa Iruela-Arispe and Mildred Leigh-Gold</p> <p>The Hypoxic Response Is Critical for Normal Murine Mammary Gland Development</p> <p>* Tiffany N. Seagroves</p> <p>Acquired Expression of a Mesenchymal-Specific Gene Periostin by Epithelial-Derived Breast Cancers Promotes Tumor Angiogenesis</p> <p>* Xiao-Fan Wang</p> <p>Vascular Endothelial Growth Factor Modulates Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability</p> <p>* Hava Avraham</p> <p>Lymphangiogenesis from Porous Alginate-VEGF-C Hydrogels in vitro</p> <p>* Mauricio A. Contreras</p>	Room 103
5:20-6:50 p.m.	<p>SYMPOSIUM 32. NOVEL THERAPEUTIC APPROACHES II</p> <p>* Co-Chair: Nancy Davidson and Christine A. Brunswick</p> <p>A Multileaf Collimator for Modulated Electron Radiation Therapy (MERT) for Breast Cancer</p> <p>* Yulin Song</p> <p>Pharmacologic Inhibitors of the Mitogen-Activated Protein Kinase (MAPK) Cascade Interact Synergistically with UCN-01 and Ionizing Radiation to Induce Apoptosis and Reduce Colony Formation in Mammary and Prostate Carcinoma Cells</p> <p>* Paul Dent</p> <p>Disruption of Growth Factor Function by Synthetic Surface-Binding Agents</p> <p>* Andrew D. Hamilton</p> <p>Characterization of IBC-1, A Novel Putative Breast Cancer Prognostic and Survival Factor</p> <p>* Ana Merlos-Suarez</p>	Room 104
5:20-6:50 p.m.	<p>SYMPOSIUM 33. GENOMIC INSTABILITY</p> <p>* Co-Chairs: Jeffrey L. Salisbury and Wish Martin</p> <p>Centrosome Amplification Drives Chromosomal Instability in Breast Tumors</p> <p>* Wilma L. Lingle</p> <p>Characterization of the STK15 Oncogene in Breast Tumors</p> <p>* Carrie A. B. Blanchette</p> <p>Centrosomal Targeting and Dynamics of Tumor-Amplified STK15/BTAK/Aurora A Kinase</p> <p>* Subrata Sen</p> <p>Functional Studies of BRCA1 and BRCA2 During Mitosis</p> <p>* Lih-Ching Hsu</p> <p>Evidence for Genomic Instability in Morphologically Normal Breast Tissues and in Benign Breast Lesions in BRCA1/2-Positive Patients with Breast Cancer</p> <p>* Bassem R. Haddad</p>	Room 105

CONCURRENT SYMPOSIA SESSIONS 29-34 (continued)		
5:20-6:50 p.m.	<p>SYMPOSIUM 34. PHARMACOGENETICS AND POPULATION STUDIES</p> <p>‣ Co-Chairs: Rebecca Blanchard Raftogianis and Betsy Lambert</p> <p>SNP in Prohibitin 3'UTR and Breast Cancer Susceptibility</p> <p>‣ Eldon R. Jupe</p> <p>Impact of Tamoxifen on the Risk of Metachronous Contralateral Breast Cancer (CBC) in Women with Germline Mutations of BRCA1 or BRCA2</p> <p>‣ Mark E. Robson</p> <p>UDP-Glucuronosyltransferase-Specific Glucuronidation Inactivates 4-Hydroxytamoxifen and Raloxifene</p> <p>‣ Jeffrey Zalatoris</p> <p>Association of Two HPC2/ELAC2 Missense Variants with Risk of Breast Cancer</p> <p>‣ Nicola Camp</p> <p>The Impact of Risk Factors and Genetic Polymorphisms on Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers and Non-Carriers. A Population-Based Study</p> <p>‣ Jorunn E. Eyfjord</p>	Room 106
6:55-8:55 p.m.	<p>POSTER SESSION/RECEPTION</p> <p>P36 - Growth Factors and Cytokines</p> <p>P37 - Tumor Suppressor Genes</p> <p>P38 - TGF-β</p> <p>P39 - Tyrosine Kinase Signaling</p> <p>P40 - Functional Studies of Biological Molecules</p> <p>P41 - Signaling: Life and Death</p> <p>P42 - Chromosome Structure</p> <p>P43 - Familial and Hereditary Carcinogenesis</p> <p>P44 - Genomic Instability</p> <p>P45 - Adhesion Molecules, Extracellular Matrix, and Cytoskeleton in Tumor Progression</p> <p>P46 - Angiogenesis</p> <p>P47 - Nutrition and Nutraceuticals</p> <p>P48 - Novel Imaging</p> <p>P49 - Magnetic Resonance Imaging</p> <p>P50 - Clinical Management of Breast Cancer</p> <p>P51 - Evolving Therapeutic Targets</p> <p>P52 - Targeted Therapies</p> <p>P53 - Hormone Therapy and Resistance</p> <p>P54 - Breast Cancer Vaccines</p> <p>P55 - Drug Resistance</p> <p>P56 - Community, Consumer, and Clinical Partnerships</p> <p>P57 - Complementary and Alternative Medicine</p> <p>P58 - Quality of Life</p> <p>P59 - Investment in the Future: Breast Cancer Training Programs</p> <p>Meeting Adjourns</p>	Hall A1
9:00 a.m.-10:00 p.m.	<p>Poster Board and Consumer Exhibit Breakdown</p>	

SUNDAY, SEPTEMBER 29, 2002

7:00 a.m. - Noon	<p>Poster Board and Consumer Exhibit Breakdown</p>	Hall A1
------------------	---	----------------

Poster Sessions at a Glance

	Poster Session Number	Day		Poster Session Number	Day
Cell Biology			Prevention		
Oncogenes	P1	Sept. 26	Lifestyle	P12	Sept. 26
Mammary Gland Development	P2	Sept. 26	Chemoprevention	P13	Sept. 26
Signal Transduction	P3	Sept. 26	Nutrition and Nutraceuticals	P47	Sept. 28
Cell Cycle	P19	Sept. 27	Detection and Diagnosis		
BRCA1/2 Tumor Suppressor Genes	P20	Sept. 27	Nuclear Medicine Imaging	P14	Sept. 26
EGF Superfamily	P21	Sept. 27	Computer-Aided Diagnosis	P15	Sept. 26
Growth Factors and Cytokines	P36	Sept. 28	Digital Imaging	P28	Sept. 27
Tumor Suppressor Genes	P37	Sept. 28	Ultrasonography	P29	Sept. 27
TGF- β	P38	Sept. 28	X-Ray Imaging	P30	Sept. 27
Tyrosine Kinase Signaling	P39	Sept. 28	Novel Imaging	P48	Sept. 28
Functional Studies of Biological Molecules	P40	Sept. 28	Magnetic Resonance Imaging	P49	Sept. 28
Signaling: Life and Death	P41	Sept. 28	Clinical and Experimental Therapeutics		
Genetics and Molecular Biology			Drug Design and Development I	P16	Sept. 26
Transcription, Translation, and Modification	P4	Sept. 26	Radiotherapy	P17	Sept. 26
Genomics and Proteomics	P5	Sept. 26	Drug Design and Development II	P31	Sept. 27
DNA Damage and Repair	P22	Sept. 27	Gene Therapy	P32	Sept. 27
Chromosome Structure	P42	Sept. 28	Immunotherapies	P33	Sept. 27
Familial and Hereditary Carcinogenesis	P43	Sept. 28	Clinical Management of Breast Cancer	P50	Sept. 28
Genomic Instability	P44	Sept. 28	Evolving Therapeutic Targets	P51	Sept. 28
Endocrinology			Targeted Therapies	P52	Sept. 28
Endocrine Carcinogenesis	P6	Sept. 26	Hormone Therapy and Resistance	P53	Sept. 28
Hormone Receptors	P7	Sept. 26	Breast Cancer Vaccines	P54	Sept. 28
Mechanisms of Hormone Action	P23	Sept. 27	Drug Resistance	P55	Sept. 28
Pathobiology			Community, Consumer, and Clinical Partnerships	P56	Sept. 28
Biomarkers I	P8	Sept. 26	Complementary and Alternative Medicine		
Tumor Progression I	P9	Sept. 26	Complementary and Alternative Medicine	P57	Sept. 28
Apoptosis	P10	Sept. 26	Biobehavioral Sciences		
Biomarkers II	P24	Sept. 27	Biobehavioral Sciences and Decision Making	P34	Sept. 27
Tumor Progression II	P25	Sept. 27	Quality of Life	P58	Sept. 28
Adhesion, Motility, and Cell Shape	P26	Sept. 27	Epidemiology		
Proteolysis in Tumor Progression	P27	Sept. 27	Epidemiology I	P18	Sept. 26
Adhesion Molecules, Extracellular Matrix, and Cytoskeleton in Tumor Progression	P45	Sept. 28	Epidemiology II	P35	Sept. 27
Angiogenesis	P46	Sept. 28	Training Programs		
Immunology			Investment in the Future: Breast Cancer Training Programs	P59	Sept. 28
Tumor Immunology	P11	Sept. 26			